Contact
Please use this form to send email to PR contact of this press release:
Human medicines European public assessment report (EPAR): Pemazyre, pemigatinib, Cholangiocarcinoma, Date of authorisation: 26/03/2021, Revision: 5, Status: Authorised
TO: